trending Market Intelligence /marketintelligence/en/news-insights/trending/-B1OXE21Ss2BP1MQcPB1LA2 content esgSubNav
In This List

Celgene completes $9B Juno acquisition

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Celgene completes $9B Juno acquisition

Summit, N.J.-based Celgene Corp. completed the $9 billion acquisition of Juno Therapeutics Inc.

The acquisition gives Celgene access to Juno's cancer therapies, including the JCAR017 CAR-T therapy, which is in late-stage trials. With U.S. regulatory approval expected in 2019, the potential treatment for blood cancer could generate $3 billion in global peak sales.